Swiss National Bank
RVNC

Swiss National Bank’s Revance Therapeutics, Inc. RVNC Stock Holding History

Swiss National Bank’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-194,650
Closed -$592K – 2469
2024
Q4 		$592K Hold
194,650
– – ﹤0.01% 2377
2024
Q3 		$1.01M Hold
194,650
– – ﹤0.01% 2213
2024
Q2 		$500K Hold
194,650
– – ﹤0.01% 2420
2024
Q1 		$958K Buy
194,650
+30,000
+18% +$178K ﹤0.01% 2245
2023
Q4 		$1.45M Sell
164,650
-20,100
-11% -$165K ﹤0.01% 2035
2023
Q3 		$2.12M Buy
184,750
+2,200
+1% +$42.3K ﹤0.01% 1804
2023
Q2 		$4.62M Buy
182,550
+5,000
+3% +$156K ﹤0.01% 1364
2023
Q1 		$5.72M Sell
177,550
-18,300
-9% -$570K ﹤0.01% 1182
2022
Q4 		$3.62M Buy
195,850
+4,300
+2% +$98.4K ﹤0.01% 1515
2022
Q3 		$5.17M Buy
191,550
+30,300
+19% +$615K ﹤0.01% 1255
2022
Q2 		$2.23M Hold
161,250
– – ﹤0.01% 1832
2022
Q1 		$3.14M Buy
161,250
+11,800
+8% +$179K ﹤0.01% 1752
2021
Q4 		$2.44M Hold
149,450
– – ﹤0.01% 1923
2021
Q3 		$4.16M Hold
149,450
– – ﹤0.01% 1594
2021
Q2 		$4.43M Buy
149,450
+12,700
+9% +$366K ﹤0.01% 1586
2021
Q1 		$3.82M Buy
136,750
+2,600
+2% +$71.9K ﹤0.01% 1622
2020
Q4 		$3.8M Buy
134,150
+17,800
+15% +$461K ﹤0.01% 1531
2020
Q3 		$2.92M Buy
116,350
+1,900
+2% +$49.8K ﹤0.01% 1517
2020
Q2 		$2.79M Buy
114,450
+24,400
+27% +$482K ﹤0.01% 1519
2020
Q1 		$1.33M Buy
90,050
+1,100
+1% +$22.8K ﹤0.01% 1680
2019
Q4 		$1.44M Buy
88,950
+15,600
+21% +$242K ﹤0.01% 1923
2019
Q3 		$954K Hold
73,350
– – ﹤0.01% 2084
2019
Q2 		$951K Buy
73,350
+3,900
+6% +$49.2K ﹤0.01% 2138
2019
Q1 		$1.09M Buy
69,450
+17,200
+33% +$298K ﹤0.01% 2013
2018
Q4 		$1.05M Buy
52,250
+1,200
+2% +$26.4K ﹤0.01% 1977
2018
Q3 		$1.27M Hold
51,050
– – ﹤0.01% 2009
2018
Q2 		$1.4M Hold
51,050
– – ﹤0.01% 1952
2018
Q1 		$1.57M Sell
51,050
-600
-1% -$19.3K ﹤0.01% 1795
2017
Q4 		$1.85M Buy
51,650
+16,200
+46% +$465K ﹤0.01% 1689
2017
Q3 		$977K Buy
35,450
+2,600
+8% +$63K ﹤0.01% 2078
2017
Q2 		$867K Hold
32,850
– – ﹤0.01% 2145
2017
Q1 		$683K Buy
32,850
+2,100
+7% +$43.1K ﹤0.01% 2244
2016
Q4 		$637K Hold
30,750
– – ﹤0.01% 2288
2016
Q3 		$498K Hold
30,750
– – ﹤0.01% 2356
2016
Q2 		$418K Hold
30,750
– – ﹤0.01% 2431
2016
Q1 		$518K Buy
30,750
+6,000
+24% +$122K ﹤0.01% 2288
2015
Q4 		$845K Buy
24,750
+3,900
+19% +$135K ﹤0.01% 1943
2015
Q3 		$620K Buy
20,850
+1,400
+7% +$42.5K ﹤0.01% 2062
2015
Q2 		$622K Buy
19,450
+6,500
+50% +$167K ﹤0.01% 2101
2015
Q1 		$268K Hold
12,950
– – ﹤0.01% 2423
2014
Q4 		$219K Buy
12,950
+2,400
+23% +$41.9K ﹤0.01% 2485
2014
Q3 		$204K Hold
10,550
– – ﹤0.01% 2431
2014
Q2 		$359K Buy
+10,550
New +$331K ﹤0.01% 2319

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Swiss National Bank's RVNC Position: Q1 2025 in Review

Swiss National Bank sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 194,650 shares — an estimated $592K sold.

Swiss National Bank first reported a position in RVNC in Q2 2014 and held it in 43 quarters. The position peaked at $5.72M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Swiss National Bank reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Swiss National Bank sold 194,650 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $592K.
  • Swiss National Bank first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 43 quarters.
  • Swiss National Bank's Revance Therapeutics, Inc. position peaked at $5.72M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Swiss National Bank's 13F filing for Q1 2025, filed 12 May 2025.